These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9184201)

  • 21. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.
    Younis HS; Crosby J; Huh JI; Lee HS; Rime S; Monia B; Henry SP
    Blood; 2012 Mar; 119(10):2401-8. PubMed ID: 22246038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.
    Leeds JM; Henry SP; Geary R; Burckin T; Levin AA
    Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):435-41. PubMed ID: 11198927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys.
    Wallace TL; Bazemore SA; Kornbrust DJ; Cossum PA
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1313-7. PubMed ID: 8819517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.
    Bennett CF; Kornbrust D; Henry S; Stecker K; Howard R; Cooper S; Dutson S; Hall W; Jacoby HI
    J Pharmacol Exp Ther; 1997 Feb; 280(2):988-1000. PubMed ID: 9023316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.
    Narayanan P; Shen L; Curtis BR; Bourdon MA; Nolan JP; Gupta S; Hoffmaster C; Zhou F; Christian B; Schaubhut JL; Greenlee S; Burel SA; Witztum JL; Engelhardt JA; Henry SP
    Toxicol Sci; 2018 Aug; 164(2):613-626. PubMed ID: 29846725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
    Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
    Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
    Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
    Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).
    Watanabe TA; Geary RS; Levin AA
    Oligonucleotides; 2006; 16(2):169-80. PubMed ID: 16764540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys.
    Working PK; Newman MS; Sullivan T; Brunner M; Podell M; Sahenk Z; Turner N
    Toxicol Sci; 1998 Nov; 46(1):155-65. PubMed ID: 9928679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
    Yacyshyn BR; Bowen-Yacyshyn MB; Jewell L; Tami JA; Bennett CF; Kisner DL; Shanahan WR
    Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense phosphorothioate oligodeoxyribonucleotide targeted against ICAM-1: synthetic and biological characterization of a process-related impurity formed during oligonucleotide synthesis.
    Ravikumar VT; Capaldi DC; Lima WF; Lesnik E; Turney B; Cole DL
    Bioorg Med Chem; 2003 Oct; 11(21):4673-9. PubMed ID: 14527564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
    Schreiber S; Nikolaus S; Malchow H; Kruis W; Lochs H; Raedler A; Hahn EG; Krummenerl T; Steinmann G;
    Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
    Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
    J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.
    Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA
    Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens.
    Yu RZ; Su JQ; Grundy JS; Geary RS; Sewell KL; Dorr A; Levin AA
    Antisense Nucleic Acid Drug Dev; 2003 Feb; 13(1):57-66. PubMed ID: 12691536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys.
    Leeds JM; Henry SP; Bistner S; Scherrill S; Williams K; Levin AA
    Drug Metab Dispos; 1998 Jul; 26(7):670-5. PubMed ID: 9660849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.